血清ELAVL4（HuD）抗原检测在小细胞肺癌诊断中的应用。

Application of Serum ELAVL4 (HuD) Antigen Assay for Small Cell Lung Cancer Diagnosis.

作者信息

Wang Feifei, Lu Jianyi, Li Shentao, Huo Xueyun, Liu Xin, Du Xiaoyan, Li Changlong, Wang Jinghui, Chen Zhenwen

机构信息

School of Basic Medical Sciences, Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research, Beijing, P.R. China.

Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, P.R. China

出版信息

Anticancer Res. 2017 Aug;37(8):4515-4522. doi: 10.21873/anticanres.11848.

DOI:10.21873/anticanres.11848

PMID:28739747

Abstract

BACKGROUND/AIM: The ELAVL4 (HuD) is a neuron-specific RNA-binding protein expressed in 100% of small cell lung cancer (SCLC) cells and over 50% of neuroblastoma cells. The aim of this study was to investigate the serum HuD concentration in SCLC patients and the possibility of its utilization as a biomarker of small cell lung cancer.

MATERIALS AND METHODS

Our study included 47 SCLC cases and 29 normal controls. Indirect competitive inhibition ELISA method was established to detect HuD antigen of serum samples. To design the ELISA system, purified antigen and real positive and negative serum samples were used, and checkerboard titration was performed. The value of current serum biomarkers (Pro-GRP, NSE, CYFRA21-1 and CEA) was obtained from a clinical laboratory.

RESULTS

The HuD antigen concentration in the SCLCgroup was significantly higher than that in the normal group (p<0.01). The cut-off value, specificity and sensitivity were 60 ng/ml, 89.7% and 74.5%, respectively. The best linear range was 9.75~600 ng/ml. The sensitivity of the HuD-ELISA assay was much better than the current biomarkers-CEA, NSE and pro-GRP. Also,it was equal to or better than the combined use of two or three indicators.

CONCLUSION

The high titres of HuD in SCLC patients and preferable consistency suggested that HuD may serve as a potential diagnostic criterium for SCLC and may serve as a marker of disease progression.

摘要

背景/目的：ELAVL4（HuD）是一种神经元特异性RNA结合蛋白，在100%的小细胞肺癌（SCLC）细胞和超过50%的神经母细胞瘤细胞中表达。本研究旨在调查SCLC患者血清中HuD的浓度及其作为小细胞肺癌生物标志物的可能性。

材料与方法

本研究纳入47例SCLC病例和29例正常对照。建立间接竞争抑制ELISA法检测血清样本中的HuD抗原。为设计ELISA系统，使用纯化抗原和实际阳性及阴性血清样本，并进行棋盘滴定。当前血清生物标志物（Pro-GRP、NSE、CYFRA21-1和CEA）的值从临床实验室获得。

结果

SCLC组中HuD抗原浓度显著高于正常组（p<0.01）。临界值、特异性和敏感性分别为60 ng/ml、89.7%和74.5%。最佳线性范围为9.75~600 ng/ml。HuD-ELISA检测的敏感性远优于当前的生物标志物CEA、NSE和Pro-GRP。此外，它等于或优于两种或三种指标的联合使用。